TeneoTwo, Inc.

The relentless expansion of Pharma’s R&D pipeline was checked somewhat last year, even as the proportion of drugs in active development for cancer reached new heights, and the burgeoning industry in A

AstraZeneca PLC is acquiring CinCor Pharma, Inc. for $1.3bn upfront in a bid to bolster its cardiorenal pipeline through the addition of a next-generation aldosterone synthase inhibitor (ASI) asset

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Success is said to breed success, but for AstraZeneca PLC , recent triumphs for its oncology portfolio are not to be taken for granted. As well as diversifying its pipeline through select deals, such